Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Tadalafil population pharmacokinetics in patients with erectile dysfunction.

Trocóniz IF, Tillmann C, Staab A, Rapado J, Forgue ST.

Eur J Clin Pharmacol. 2007 Jun;63(6):583-90. Epub 2007 Apr 13.

PMID:
17431603
2.

Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.

Forgue ST, Phillips DL, Bedding AW, Payne CD, Jewell H, Patterson BE, Wrishko RE, Mitchell MI.

Br J Clin Pharmacol. 2007 Jan;63(1):24-35. Epub 2006 Jul 21.

3.

Model-based drug development: the road to quantitative pharmacology.

Zhang L, Sinha V, Forgue ST, Callies S, Ni L, Peck R, Allerheiligen SR.

J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):369-93. Epub 2006 Jun 13.

PMID:
16770528
4.

Tadalafil pharmacokinetics in healthy subjects.

Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI.

Br J Clin Pharmacol. 2006 Mar;61(3):280-8.

5.

Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.

Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H, Payne CD, Forgue ST, Eckstein J, Wrighton SA, Phillips DL.

Clin Pharmacol Ther. 2005 Jan;77(1):63-75.

PMID:
15637532
6.

Population dose-response model for tadalafil in the treatment of male erectile dysfunction.

Staab A, Tillmann C, Forgue ST, Mackie A, Allerheiligen SR, Rapado J, Trocóniz IF.

Pharm Res. 2004 Aug;21(8):1463-70.

PMID:
15359583
7.

Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study.

Delaloge S, Llombart A, Di Palma M, Tourani JM, Turpin F, Ni L, Forgue ST, Le Chevalier T.

Am J Clin Oncol. 2004 Jun;27(3):289-93.

PMID:
15170150
8.

Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.

Abraham E, Naum C, Bandi V, Gervich D, Lowry SF, Wunderink R, Schein RM, Macias W, Skerjanec S, Dmitrienko A, Farid N, Forgue ST, Jiang F.

Crit Care Med. 2003 Mar;31(3):718-28.

PMID:
12626975
9.

Confidence interval criteria for assessment of dose proportionality.

Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST.

Pharm Res. 2000 Oct;17(10):1278-83.

PMID:
11145235
10.
11.

Characterization of a 7 day 17 beta-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women.

Boyd RA, Zegarac EA, Eldon MA, Sedman AJ, Forgue ST.

Biopharm Drug Dispos. 1996 Aug;17(6):459-70.

PMID:
8866037
12.
13.

Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine.

Yang BB, Hounslow NJ, Sedman AJ, Forgue ST.

J Clin Pharmacol. 1996 Apr;36(4):356-60.

PMID:
8728350
14.

Inhibition of tacrine oral clearance by cimetidine.

Forgue ST, Reece PA, Sedman AJ, deVries TM.

Clin Pharmacol Ther. 1996 Apr;59(4):444-9.

PMID:
8612390
15.

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.

Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, Martin RR.

Antimicrob Agents Chemother. 1992 Mar;36(3):552-7.

16.

Disposition of the cephalosporin cefepime in normal and renally impaired subjects.

Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Halstenson CE, Opsahl JA, Pittman KA.

Drug Metab Dispos. 1991 Jan-Feb;19(1):68-73.

PMID:
1673424
17.

Pharmacokinetics of cefepime in subjects with renal insufficiency.

Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA.

Clin Pharmacol Ther. 1990 Sep;48(3):268-76.

PMID:
2401125
18.

Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.

Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Martin RR.

Antimicrob Agents Chemother. 1990 Jun;34(6):1118-22.

19.

N-oxidation of N-methylpyrrolidine released in vivo from cefepime.

Forgue ST, Kari P, Barbhaiya R.

Drug Metab Dispos. 1987 Nov-Dec;15(6):808-15.

PMID:
2893706
20.

Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys.

Forgue ST, Shyu WC, Gleason CR, Pittman KA, Barbhaiya RH.

Antimicrob Agents Chemother. 1987 May;31(5):799-804.

21.

High-performance liquid chromatographic analysis of a novel carbapenem antibiotic in human plasma and urine.

Forgue ST, Pittman KA, Barbhaiya RH.

J Chromatogr. 1987 Mar 6;414(2):343-53.

PMID:
3571402
22.

High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine.

Barbhaiya RH, Forgue ST, Shyu WC, Papp EA, Pittman KA.

Antimicrob Agents Chemother. 1987 Jan;31(1):55-9.

23.

Determination of tiodazosin concentrations in human plasma with a fluorescence high-performance liquid chromatographic method.

Forgue ST, Van Harken DR, Smyth RD.

J Chromatogr. 1985 Jul 12;342(1):221-7. No abstract available.

PMID:
4044753
24.
25.

Direct evidence that an arene oxide is a metabolic intermediate of 2,2',5,5'-tetrachlorobiphenyl.

Forgue ST, Preston BD, Hargraves WA, Reich IL, Allen JR.

Biochem Biophys Res Commun. 1979 Nov 28;91(2):475-83. No abstract available.

PMID:
42397
26.

Rat brain tubulin: subunit heterogeneity and phosphorylation.

Forgue ST, Dahl JL.

J Neurochem. 1979 Mar;32(3):1015-25. No abstract available.

PMID:
430036
27.

The turnover rate of tubulin in rat brain.

Forgue ST, Dahl JL.

J Neurochem. 1978 Nov;31(5):1289-97. No abstract available.

PMID:
702174

Supplemental Content

Loading ...
Support Center